Skip to main content
Log in

Economic benefits with high-dose IIV3 in elderly US patients

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. quality-adjusted life-year

Reference

  • Raviotta JM, et al. Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults. Journal of the American Geriatrics Society : 6 Oct 2016. Available from: URL: http://dx.doi.org/10.1111/jgs.14323

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Economic benefits with high-dose IIV3 in elderly US patients. PharmacoEcon Outcomes News 765, 15 (2016). https://doi.org/10.1007/s40274-016-3500-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3500-8

Navigation